Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
30actual
Sites
11
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-09 | actual | When the study began enrolling |
| Primary completion | 2025-10-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-15 | actual | The whole study's end, after follow-up |
| First posted | 2021-07-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced NSCLC
Interventions
- Drug: REGN5093-M114
- Drug: Cemiplimab
Primary outcomes
what the primary-completion date above is the date OFDose limiting toxicities (DLTs)
measured Up to 28 days
Treatment-emergent adverse events (TEAEs)
measured Through study completion, an average of 2 years
Serious adverse events (SAEs)
measured Through study completion, an average of 2 years
TEAEs leading to study treatment discontinuation
measured Through study completion, an average of 2 years
TEAEs leading to death
measured Through study completion, an average of 2 years
Laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE])
measured Through study completion, an average of 2 years
Concentrations of REGN5093-M114 in serum
measured Through study completion, an average of 2 years
Total monoclonal antibodies (REGN5093- M114 plus unconjugated antibody) in serum
measured Through study completion, an average of 2 years
Concentrations of M24 in plasma
measured Through study completion, an average of 2 years
Concentrations of cemiplimab when given in combination with REGN5093-M114
measured Through study completion, an average of 2 years
Objective response rate (ORR)
measured Through study completion, an average of 2 years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed